Exicure, Inc. (Nasdaq: XCUR) has reported its financial results for the first quarter of 2025. The company recorded a net income of $3.0 million for the quarter ended March 31, 2025, a significant improvement from the net loss of $0.8 million for the same period in 2024. This $3.8 million increase in net income was primarily due to a $6 million gain from the reversal of the lease liability, which was partly offset by increased operating expenses following the acquisition of GPCR Therapeutics USA Inc. The company's cash and cash equivalents stood at $10.4 million as of March 31, 2025, down from $12.5 million at the end of 2024. Research and development expenses were reported at $0.8 million for the first quarter of 2025, compared to no expenses in the first quarter of 2024, reflecting research activities following the acquisition of GPCR USA. General and administrative expenses rose to $2.2 million in the first quarter of 2025, up from $1.3 million in the previous year's first quarter, due to additional expenses related to the acquisition and increased professional services. Exicure has acknowledged that its current cash position is insufficient to sustain operations, emphasizing the need for substantial additional financing to cover expenses and explore strategic alternatives. The company is actively seeking capital to support its ongoing activities, though there is no guarantee of securing the necessary funding.